JK500 cells
Relapsed Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
124 Active assets in the Relapsed Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
ASPARAGINASE Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 3 | BB |
THIOGUANINE ANHYDROUS Incyte Corporation | Phase 3 | BB |
Idarubicine Affiliated Hospital of Nantong University | Phase 3 | BB |
Daunorubicin Richard Stone, MD | Phase 3 | BB |
View all 50 →
Same molecule, other indications
JK500 cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →